How the hunger for a new weight loss drug is feeding an industry of fakes

The allure of a new weight loss drug, particularly one displaying early promise in clinical trials, is often celebrated by its developers. However, the experimental drug retatrutide has become a source of concern not just for Eli Lilly, the pharmaceutical company responsible for its development, but also for regulatory bodies worldwide.

Despite the drug not yet receiving approval for human use, counterfeit versions are already circulating in the black market. These illicit copies are being sold in various locations, from gyms and nail salons to social media platforms and even by street vendors in the UK. The normalization of the black market for this unapproved drug has led many to believe it is safe to inject, despite the risks involved.

Experts have expressed their alarm at the prevalence of these counterfeit products, stating that it is one of the first times they have witnessed experimental drugs like retatrutide being readily available in such a manner. The availability of fake retatrutide has led to a dangerous normalization of the drug, with people openly discussing its dealers, the best sources, and even posting before and after photos on social media, claiming that it has transformed their lives.

However, the reality is that real retatrutide is still undergoing safety and efficacy testing. Only 50% of drugs in Phase III trials in the US are approved by the FDA, indicating the high rate of failure due to inadequate results in diverse populations or unexpected safety hazards. The counterfeit versions available may contain unknown ingredients, harmful contaminants, or different active ingredients altogether, posing significant risks to users.

Despite these warnings, individuals are taking the risk of using these unapproved versions, with some experiencing severe side effects such as nausea, vomiting, diarrhea, and even kidney failure.